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Daily MME Meta Analysis
Adapting a method recently developed by FDA to analyze a related opioid methods question, we used meta analytic techniques to test the
impact of the four definitions in the real-world. The general set up is to compare opioid use in FL vs. CA across the 4 definitions of daily
MME. We previously observed that Florida had higher unadjusted levels of opioid use, presumably an interaction with an older population
and the enactment of clinical pain management legislation. We took two approaches, 1) treating daily MME as categorical by comparing
the proportion of "high dose" users among opioid recipients, and 2) comparing means of daily MME between the states in a continuous




Comparing "High Dose" patients in CA and FL


























Run meta analysis command using fixed effects model. Since there is no sampling variation, fixed effects is the preferred a priori
specification.
In [4]: meta summarize, fixed eform 
For the sake of completeness, random effects models are also run, using the Sidik-Jonkman random(sj)  estimator because tau is
expected to be large Veroniki et al., with DerSimonian–Laird random(dl)  as well separately for comparison, but fixed effects (above) is
the more technically correct model specification.
In [5]: meta summarize, random(sj) eform 
In [6]: meta summarize, random(dl) eform 
Results are similar, but SJ is preferred based on simulations in Veroniki et al. The fixed effects model over emphasizes precision (e.g.,
confuses it for more information) in D4 due to the higher number of high dose patients. Since there is no sampling variation
Interpretation
The proportion of "high dose" patients was consitently higher in Florida across all variants. However, the magnitude of the difference varied
greatly: 84.3% (95% CI: 82.7%, 86.0%) for Definition 3 (defined observation window); 64.0% (95% CI: 62.5%, 65.5%) for Definition 1 (sum
of days supply); 59.2% (95% CI: 58.0%, 60.3%) for Definition 2 (accounting for overlap days); and 38.7% (95% CI: 37.9%, 39.4%) for
Definition 4 (maximum daily dose). Metrics confirmed very high heterogenity between the definitions, with I2 greater than 99% and H2 of
1086, supported by tests of hetereogenity chi2 of 3257 on 3 degrees of freedom (p<0.0001), and overall effect z=237, with 1 degree of
freedom and p<0.0001.
Meta Analysis of Means by Type of Opioid
In this meta analysis we examine the impact of definitional variation on acute vs. chronic pain patients, measured by opioid formulation
type. We stratified the sample into three sub-groups: 1) patients receiving on only immediate-release or short-acting opioids labeled for
acute pain (hereafter immediate-release; 2) patients receiving only extended-release or long-acting opioids generally labeled for chronic
pain (hereafter extended-release); and 3) patients receiving both immediate-release and extended-release opioids contemporaneously
within the 3 month observation period (e.g., chronic pain patients receiving opioids for breakthrough pain or during taper).
Continuing with the approach in the previous meta analysis, we calculated mean differences in daily MME between Florida and California,



































ER only group had lower mean daily MME in Florida than California?!
Heterogeneity by I  was high for all 3 definitions
Heterogeneity was lowest for ER-only group by both I  and X
For ER+IR group, the definitional variants would have resulted in us concluding that the average dose was 8.8 (8.3, 9.3) milligrams to
17.2 (15.1, 19.3) milligrams higher in Florida.
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===== Proportion of high dose patients FL vs CA greater than 90 daily MME ===== 
 
Definition 1 
 
 
                 |   Exposed   Unexposed  |      Total 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Cases |     87295       87078  |     174373 
        Noncases |   1398296     2343792  |    3742088 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Total |   1485591     2430870  |    3916461 
                 |                        | 
            Risk |  .0587611    .0358217  |   .0445231 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­ 
 Risk difference |         .0229394       |    .0224949    .0233839  
      Risk ratio |         1.640376       |    1.625414    1.655475  
 Attr. frac. ex. |         .3903837       |    .3847723    .3959439  
 Attr. frac. pop |         .1954347       | 
                 +­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                               chi2(1) = 11405.78  Pr>chi2 = 0.0000 
 
Definition 2 
 
 
                 |   Exposed   Unexposed  |      Total 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Cases |    136995      140822  |     277817 
        Noncases |   1348596     2290048  |    3638644 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Total |   1485591     2430870  |    3916461 
                 |                        | 
            Risk |  .0922158    .0579307  |   .0709357 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­ 
 Risk difference |         .0342851       |    .0337349    .0348353  
      Risk ratio |          1.59183       |    1.580486    1.603256  
 Attr. frac. ex. |         .3717922       |    .3672831    .3762692  
 Attr. frac. pop |         .1833353       | 
                 +­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                               chi2(1) = 16446.29  Pr>chi2 = 0.0000 
 
Definition 3 
 
 
                 |   Exposed   Unexposed  |      Total 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Cases |     97346       86407  |     183753 
        Noncases |   1388245     2344463  |    3732708 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Total |   1485591     2430870  |    3916461 
                 |                        | 
            Risk |  .0655268    .0355457  |   .0469181 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­ 
 Risk difference |         .0299811       |    .0295201    .0304421  
      Risk ratio |         1.843451       |    1.827062    1.859988  
 Attr. frac. ex. |         .4575392       |    .4526731    .4623621  
 Attr. frac. pop |         .2423885       | 
                 +­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                               chi2(1) = 18534.92  Pr>chi2 = 0.0000 
 
Definition 4 
 
 
                 |   Exposed   Unexposed  |      Total 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Cases |    211429      249471  |     460900 
        Noncases |   1274162     2181399  |    3455561 
­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­ 
           Total |   1485591     2430870  |    3916461 
                 |                        | 
            Risk |  .1423198    .1026262  |   .1176828 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­ 
 Risk difference |         .0396936       |    .0390145    .0403727  
      Risk ratio |         1.386778       |    1.379279    1.394318  
 Attr. frac. ex. |         .2789041       |    .2749835    .2828035  
 Attr. frac. pop |         .1279419       | 
                 +­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                               chi2(1) = 13991.68  Pr>chi2 = 0.0000 
 
 
. gen lnirr=ln(irr) 
 
. gen lnll=ln(ll) 
 
. gen lnul=ln(ul) 
 
. qui: meta set lnirr lnll lnul, studylabel(label) 
  Effect­size label:  Effect Size 
        Effect size:  lnirr 
          Std. Err.:  _meta_se 
        Study label:  label 
 
Meta­analysis summary                                Number of studies =      4 
Fixed­effects model                                  Heterogeneity: 
Method: Inverse­variance                                       I2 (%) =   99.91 
                                                                   H2 = 1085.83 
 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                       Study |        exp(ES)    [95% Conf. Interval]  % Weight 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
      D1. Sum of days supply |          1.640       1.625       1.655     15.27 
D2. Accounting for overlap~s |          1.592       1.580       1.603     25.06 
D3. Defined observation wi~w |          1.843       1.827       1.860     16.07 
      D4. Maximum daily dose |          1.387       1.379       1.394     43.60 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                  exp(theta) |          1.542       1.536       1.547 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
Test of theta = 0: z = 237.00                               Prob > |z| = 0.0000 
Test of homogeneity: Q = chi2(3) = 3257.49                    Prob > Q = 0.0000 
  Effect­size label:  Effect Size 
        Effect size:  lnirr 
          Std. Err.:  _meta_se 
        Study label:  label 
 
Meta­analysis summary                                Number of studies =      4 
Random­effects model                                 Heterogeneity: 
Method: Sidik­Jonkman                                            tau2 =  0.0137 
                                                               I2 (%) =   99.90 
                                                                   H2 =  954.41 
 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                       Study |        exp(ES)    [95% Conf. Interval]  % Weight 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
      D1. Sum of days supply |          1.640       1.625       1.655     24.99 
D2. Accounting for overlap~s |          1.592       1.580       1.603     25.00 
D3. Defined observation wi~w |          1.843       1.827       1.860     24.99 
      D4. Maximum daily dose |          1.387       1.379       1.394     25.02 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                  exp(theta) |          1.607       1.433       1.803 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
Test of theta = 0: z = 8.11                                 Prob > |z| = 0.0000 
Test of homogeneity: Q = chi2(3) = 3257.49                    Prob > Q = 0.0000 
  Effect­size label:  Effect Size 
        Effect size:  lnirr 
          Std. Err.:  _meta_se 
        Study label:  label 
 
Meta­analysis summary                                Number of studies =      4 
Random­effects model                                 Heterogeneity: 
Method: DerSimonian­Laird                                        tau2 =  0.0156 
                                                               I2 (%) =   99.91 
                                                                   H2 = 1085.83 
 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                       Study |        exp(ES)    [95% Conf. Interval]  % Weight 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
      D1. Sum of days supply |          1.640       1.625       1.655     24.99 
D2. Accounting for overlap~s |          1.592       1.580       1.603     25.00 
D3. Defined observation wi~w |          1.843       1.827       1.860     24.99 
      D4. Maximum daily dose |          1.387       1.379       1.394     25.01 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
                  exp(theta) |          1.607       1.422       1.816 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
Test of theta = 0: z = 7.61                                 Prob > |z| = 0.0000 
Test of homogeneity: Q = chi2(3) = 3257.49                    Prob > Q = 0.0000 
 
 
     definit~n       n_fl       m_fl      sd_fl       n_ca       m_ca      sd_ca 
 
 
 
  Effect­size label:  Mean Diff. 
        Effect size:  _meta_es 
          Std. Err.:  _meta_se 
 
Meta­analysis summary                     Number of studies =      4 
Fixed­effects model                       Heterogeneity: 
Method: Inverse­variance                            I2 (%) =   98.63 
                                                        H2 =   72.98 
 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
            Study |     Mean Diff.    [95% Conf. Interval]  % Weight 
­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
          Study 1 |          3.738       3.359       4.116      3.92 
          Study 2 |          3.514       3.135       3.894      3.90 
          Study 3 |          2.240       2.160       2.319     89.72 
          Study 4 |          5.105       4.626       5.584      2.45 
­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
            theta |          2.418       2.343       2.493 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
Test of theta = 0: z = 63.18                     Prob > |z| = 0.0000 
Test of homogeneity: Q = chi2(3) = 218.94          Prob > Q = 0.0000 
 
 
     definit~n       n_fl       m_fl      sd_fl       n_ca       m_ca      sd_ca 
 
 
 
  Effect­size label:  Mean Diff. 
        Effect size:  _meta_es 
          Std. Err.:  _meta_se 
 
Meta­analysis summary                     Number of studies =      4 
Fixed­effects model                       Heterogeneity: 
Method: Inverse­variance                            I2 (%) =   86.38 
                                                        H2 =    7.34 
 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
            Study |     Mean Diff.    [95% Conf. Interval]  % Weight 
­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
          Study 1 |         ­3.316      ­4.806      ­1.826     35.11 
          Study 2 |         ­6.827      ­8.745      ­4.909     21.19 
          Study 3 |         ­5.916      ­7.415      ­4.418     34.70 
          Study 4 |        ­10.637     ­13.578      ­7.695      9.01 
­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
            theta |         ­5.622      ­6.504      ­4.739 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
Test of theta = 0: z = ­12.48                    Prob > |z| = 0.0000 
Test of homogeneity: Q = chi2(3) = 22.03           Prob > Q = 0.0001 
 
 
     definit~n       n_fl       m_fl      sd_fl       n_ca       m_ca      sd_ca 
 
 
 
  Effect­size label:  Mean Diff. 
        Effect size:  _meta_es 
          Std. Err.:  _meta_se 
 
Meta­analysis summary                     Number of studies =      4 
Fixed­effects model                       Heterogeneity: 
Method: Inverse­variance                            I2 (%) =   98.34 
                                                        H2 =   60.27 
 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
            Study |     Mean Diff.    [95% Conf. Interval]  % Weight 
­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
          Study 1 |          8.764       8.267       9.260     69.06 
          Study 2 |         16.169      15.031      17.307     13.13 
          Study 3 |         10.360       9.255      11.464     13.94 
          Study 4 |         17.203      15.111      19.296      3.88 
­­­­­­­­­­­­­­­­­­+­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
            theta |         10.286       9.873      10.698 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
Test of theta = 0: z = 48.90                     Prob > |z| = 0.0000 
Test of homogeneity: Q = chi2(3) = 180.81          Prob > Q = 0.0000 
